8/18/2008

The FDA approved Prestwick Pharmaceuticals' Xenazine, making it the first medication for Huntington's disease to obtain U.S. clearance. The drug, which decreases levels of dopamine, is designed to suppress chorea -- involuntary body movements associated with the disease. Xenazine can cause depression or increase the risk of suicide in some patients, the FDA said.

Related Summaries